50 results
SC 14D9/A
EX-99
PNT
POINT Biopharma Global Inc.
18 Dec 23
Tender offer solicitation (amended)
8:14am
at a future medical congress.
About the SPLASH Trial
The phase 3 SPLASH trial is a multicenter, randomized, open label assessment of 177Lu-PNT2002 in patients
SC 14D9
PNT
POINT Biopharma Global Inc.
13 Oct 23
Tender offer solicitation
7:11am
their assessment of the Internal Data and conducted such financial studies and analyses and took into account such information as Centerview deemed appropriate … and probability adjustments reflecting POINT’s management’s good faith assessment as to the probability of success for POINT’s product candidates and pipeline
SC14D9C
EX-2.1
PNT
POINT Biopharma Global Inc.
3 Oct 23
Written communication relating to third party tender offer
7:37am
outstanding), and there are no outstanding requests, agreements, consents or waivers to extend, the statutory period of limitations applicable to the assessment
8-K
EX-2.1
PNT
POINT Biopharma Global Inc.
3 Oct 23
Tender and Support Agreement
7:35am
outstanding), and there are no outstanding requests, agreements, consents or waivers to extend, the statutory period of limitations applicable to the assessment
ARS
c0fepjte gyj7lcb
1 May 23
Annual report to shareholders
1:52pm
424B5
2wg6gdtq8pl
14 Sep 22
Prospectus supplement for primary offering
4:12pm
424B5
ctbp9w0qg3itiutcdr5
13 Sep 22
Prospectus supplement for primary offering
5:19pm
8-K
EX-99.2
uqegwq bed
12 Sep 22
POINT Biopharma Provides Updated Efficacy and Safety Data from the Lead-In Cohort of the Phase 3 SPLASH Trial in mCRPC at ESMO Congress 2022
7:54am
8-K
EX-99.1
ypsov4u f1j63g
12 Sep 22
POINT Biopharma Provides Updated Efficacy and Safety Data from the Lead-In Cohort of the Phase 3 SPLASH Trial in mCRPC at ESMO Congress 2022
7:54am
8-K
EX-99.1
8lur37q
6 Sep 22
POINT Biopharma Announces Poster Presentation at ESMO Congress 2022 Containing Efficacy & Safety Data from Lead-In Cohort of Phase 3 SPLASH Trial
8:11am
S-3
EX-4.6
8po 6bhw2aa6
1 Jul 22
Shelf registration
4:13pm
S-3
EX-4.7
mghzdy21t oa
1 Jul 22
Shelf registration
4:13pm
DEF 14A
wrl95wyg98n4 j7
28 Apr 22
Definitive proxy
8:36am
424B3
yxv 2j3gbgn650q
31 Mar 22
Prospectus supplement
11:42am
POS AM
dgfqjno8 smh
25 Mar 22
Prospectus update (post-effective amendment)
8:41am
8-K
EX-99.1
gn23 8uysjc1z
25 Mar 22
POINT Biopharma Reports Fiscal 2021 Financial Results and Provides Business Update
8:22am